Resolution Therapeutics Builds Momentum as EMERALD Liver Cell Therapy Trial Gains Recognition

Resolution Therapeutics – a clinical-stage biotech developing regenerative macrophage cell therapies for end-stage liver disease – saw a busy week marked by clinical execution, industry recognition, and heightened visibility. The company continued to spotlight its Phase I/II EMERALD trial of lead candidate RTX001, which is enrolling patients with advanced liver disease in the U.K. and Spain.

EMERALD is being conducted across eight NHS hospitals in the U.K. and seven sites in Spain, underscoring a relatively broad early clinical footprint. Investigators at Royal Liverpool University Hospital and Glasgow Royal Infirmary highlighted the heavy burden of liver disease and the need for alternatives or complements to liver transplantation.

The company’s RTX001 and EMERALD program received “Best Therapeutic R&D Programme of the Year” at the 2026 One Nucleus Awards, reflecting growing recognition within the U.K. life sciences sector. While the award does not alter fundamentals, it may modestly enhance Resolution’s profile with potential partners and investors ahead of interim EMERALD data expected later this year.

Resolution also gained scientific visibility through a BioCentury feature on emerging fibrosis treatments, where CEO Amir Hefni discussed the firm’s regenerative macrophage platform targeting the root causes of fibrosis. In parallel, Hefni appeared on Drug Discovery World’s podcast to explain how RTX001 could reshape the liver disease treatment landscape if clinical outcomes are favorable.

Policy engagement was a notable theme as senior U.K. health policymakers, including the Secretary of State for Health and Social Care, received a briefing on Resolution’s technology and EMERALD trial at Edinburgh BioQuarter. This interaction underscores governmental awareness of liver disease burden and may support a receptive environment for advanced cell therapies over time.

At the Advanced Therapies conference in London, Resolution showcased its expertise in regenerative macrophage science and advanced therapy manufacturing. Company leaders contributed to sessions on CMC, AI- and automation-enabled cell therapy production, and supply chain and logistics, signaling early focus on scalability and industrialization.

Collectively, the week’s developments reinforced Resolution Therapeutics’ positioning in liver-focused cell therapy, combining active clinical recruitment, rising industry and policy visibility, and investment in manufacturing know-how. While pivotal clinical data remain the key value driver, the company’s recent progress suggests growing momentum as EMERALD advances.